1,3-Dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes
摘要:
In order to study the structure-activity relationships of dioxolane nucleosides as potential anti-HIV-1 agents, various enantiomers of pure dioxolanylpurine nucleosides were synthesized and evaluated against HIV-1 in human peripheral blood mononuclear cells. The enantiomerically pure key intermediate 1, which was synthesized in nine steps from 1,6-anhydro-beta-D-mannose, was condensed with 6-chloropurine, 6-chloro-2-fluoropurine, and 2,6-dichloropurine in the presence of TMS triflate. The chloro or fluoro substituents were readily converted into amino, N-methylamino, hydroxy, methoxy, thiol, and methylthio under appropriate reaction conditions. Upon evaluation of these dioxolanes, the guanine derivative 24 exhibited the most potent anti-HIV-1 activity without cytotoxicity up to 100 muM in various cells. The decreasing antiviral activity order of beta-isomers was as follows: guanine > 6-chloro-2-aminopurine > 2-fluoroadenine greater-than-or-equal-to adenine greater-than-or-equal-to 2,6-diaminopurine > hypoxanthine > 2-chloroadenine > 6-chloropurine congruent-to N6-methyladenine congruent-to 6-mercaptopurine congruent-to 6-(methylthio)purine.
[EN] ENANTIOMERICALLY PURE beta -D-DIOXOLANE NUCLEOSIDES WITH SELECTIVE ANTI-HEPATITIS B VIRUS ACTIVITY<br/>[FR] NUCLEOSIDES DE beta -D-DIOXOLANE A PURETE ENANTIOMERE ET A ACTIVITE DIRIGEE SELECTIVEMENT CONTRE LE VIRUS DE L'HEPATITE B
申请人:EMORY UNIVERSITY
公开号:WO1994009793A1
公开(公告)日:1994-05-11
(EN) The invention is a method for the treatment of humans infected with HBV that includes administering an HBV treatment amount of an enatiomerically pure $g(b)-D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2 or H, and X is selected from the group consisting of alkyl, acyl, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt.(FR) Procédé de traitement des malades atteints du virus de l'hépatite B. Il consiste à administrer une dose efficace d'un nucléoside de $g(b)-D-dioxolanyl purine à pureté énantiomère de la formule (I), dans laquelle R représente OH, Cl, NH2 ou H; et X est sélectionné dans le groupe constitué d'alkyle, acyle, monophosphate, diphosphate, triphosphate, ou son sel pharmaceutiquement acceptable.
Enantiomerically pure beta-D-dioxolane-nucleosides
申请人:UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
公开号:EP1081148A2
公开(公告)日:2001-03-07
A method and composition for the treatment of humans infected with HIV that includes administration of an HIV treatment amount of an enantiomerically pure β-D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.
一种用于治疗感染艾滋病毒的人类的方法和组合物,包括施用对映体纯的式(I)β-D-二氧戊环嘌呤核苷的艾滋病毒治疗量,其中 R 是 OH、Cl、NH2 或 H,或该化合物的药学上可接受的盐或衍生物,可选地在药学上可接受的载体或稀释剂中。
ENANTIOMERICALLY PURE $g(b)-D-DIOXOLANE-NUCLEOSIDES
申请人:UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
公开号:EP0656778A1
公开(公告)日:1995-06-14
EP0656778A4
申请人:——
公开号:EP0656778A4
公开(公告)日:1995-08-02
ENANTIOMERICALLY PURE BETA-D-DIOXOLANE-NUCLEOSIDES
申请人:UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.